認知症の脳画像診断　早期検出と鑑別をめざして

出版社： メジカルビュー社
著者：
発行日： 2015-09-20
分野： 臨床医学：内科  >  老人医学
ISBN： 9784758315845
電子書籍版： 2015-09-20 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

8,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

8,800 円(税込)

購入する

商品紹介

認知症の画像診断は，早期検出および鑑別診断上からも必ず不可欠なものとなってきている。そこで本書は，「早期検出」，「鑑別診断」，「将来展望」を3本柱として構成し，臨床における画像診断の現状と今後期待される発展について一望できるようコンパクトにまとめた。

目次

  • 認知症の脳画像診断　早期検出と鑑別をめざして

    ―目次―

    I　認知症の画像診断―早期検出―
    　認知症の診断
    　認知症の臨床
    　アルツハイマー型認知症のMRI診断
    　アルツハイマー型認知症の脳血流SPECT（IMP）診断
    　MCIクリニックにおける診断・治療戦略

    II　認知症の画像診断―鑑別診断―
    　変性性疾患との鑑別
    　特発性正常圧水頭症
    　血管性認知症
    　糖尿病性認知症

    III　認知症の画像診断―将来展望―
    　認知症の新しい画像診断

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 認知症の画像診断 - 早期検出 -

P.15 掲載の参考文献
1) 西村恒彦:脳核医学検査の特徴. 第3版 最新脳SPECT/PETの臨床(西村恒彦編), メジカルビュー社, p2-8, 2012.
 
2) de Leon MJ, et al.:The radiologic prediction of Alzheimer disease;the atrophic hippocampal formation. Am J Neuroradiol, 14:897-906, 1993.
PubMed
3) Hirata Y, et al.:Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 382:269-274, 2005.
PubMed
4) Ishii K, et al.:Computer-assisted diagnostic system for neurodegenerative dementia using brain SPECT and 3D-SSP. Eur J Nucl Med Mol Imaging, 36:831-840, 2009.
PubMed
5) Minoshima S, et al.:Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol, 42:85-94, 1997.
PubMed
6) Warr L, et al.:Identification of biomarkers in Lewy-body disorders. Q J Nucl Med Mol Imaging, 56:39-54, 2012.
PubMed
7) Klunk WE, et al.:Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol, 55:306-319, 2004.
PubMed
8) Okamura N, et al.:Novel 18F-labeledarylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med, 54:1420-1427, 2013.
PubMed
9) Sperling RA, et al.:Toward defining the preclinical stages of Alzheimer's disease:Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7:280-292, 2011.
PubMed
P.23 掲載の参考文献
1) 米国精神医学会 編, 日本精神神経学会翻訳 監修, 高橋三郎, 大野裕 監訳:DSM-5 精神疾患の診断・統計マニュアル. 医学書院, 2014. (American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder Fifth Edition. Arlington VA USA, 2013. )
 
2) Alzheimer A:Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychish-Gerichitliche Medizin 64, 146-148, 1907.
 
3) Grundke-Iqbal I, et al.:Abnormal phosphorylation of the microtubule-associated protein tau in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83:4913-4917, 1986.
PubMed
4) Glenner GG, et al.:Alzheimer's disease:initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 120:885-890, 1984.
PubMed
5) Burns A, et al.:Psychiatric phenomena in Alzheimer's disease. IV:Disorders of behaviour. British J Psychiat 157, 86-94, 1990.
 
6) 国際老年精神医学会 編, 日本老年精神医学会 監訳:第2版認知症の行動と心理症状BPSD. アルタ出版, 2013. (International Psychogeriatric association. Behavioral and Psychological Symptoms of Dementia. 2010. )
 
7) Zubenko GS, et al.:Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 48:619-624, 1991.
PubMed
8) McKhann GM, et al.:The diagnosis of dementia due to Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3):263-269, 2011.
PubMed
9) Sperling RA, et al.:Toward defining the preclinical stages of Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3):280-292, 2011.
PubMed
10) Neary D, et al.:Frontotemporal lobar degeneration:a consensus on clinical diagnosis criteria. Neurology 51:1546-1554, 1998.
 
11) McKeith IG, et al.:Diagnosis and management of dementia with Lewy bodies:third report of the DLB consortium. Neurology 65:1863-1872, 2005.
PubMed
12) Roman GC, et al.:Vascular dementia:diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250-260, 1993.
 
P.28 掲載の参考文献
1) Folstein MF, et al.:"Mini-Mental State":a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198, 1975.
 
2) 加藤伸司 ほか:改訂長谷川式簡易知能評価スケール(HDS-R)の作成. 老年精神医学雑誌, 2:1339-1347, 1991.
Medical*Online
3) 福永知子 ほか:新しい老人用精神機能検査の作成-N式精神機能検査-. 老年精神医学, 5:221-231, 1988.
 
4) de Wall C, et al.:The Extended Rivermead Behavioural Memory Test:a measure of everyday memory performance in normal adults. Memory. 2:149-166, 1994.
PubMed
5) Rosen W.G, et al.:A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141:1356-1364, 1984.
PubMed
6) Reisberg B:Dementia:a systematic approach to identifying reversible causes. Geriatrics. 41(4):30-46, 1986.
PubMed
7) Morris JC:The Clinical Dementia Rating (CDR):current version and scoring rules. Neurology. 43(11):2412-2414, 1993.
PubMed
8) Cummings JL, et al.:The Neuropsychiatric Inventory:comprehensive assessment of psychopathology in dementia. Neurology. 44:2308-2314, 1994.
PubMed
9) Zarit SH, Et al.:Relatives of the impaired elderly:correlates of feelings of burden. Gerontologist, 20:649-655, 1980.
PubMed
P.37 掲載の参考文献
1) Holmes C, et al.:Long-term effects of Abeta42 immunisation in Alzheimer's disease:follow-up of a randomised, placebo-controlled phase I trial. Lancet. 372:216-223, 2008.
PubMed
2) Salloway S, et al.:A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 73:2061-2070, 2009.
PubMed
3) Salloway S, et al.:Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 23;370(4):322-333, 2014.
 
4) Bateman RJ, et al.:A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 66:48-54, 2009.
PubMed
5) Green RC, et al.:Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease:a randomized controlled trial. JAMA. 302:2557-2564, 2009.
PubMed
6) Lannfelt L, et al.:Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease:a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7:779-786, 2008.
PubMed
7) Forlenza OV, et al.:Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment:randomised controlled trial. Br J Psychiatry. 198(5):351-356, 2011.
PubMed
8) Asuni AA, et al.:Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 27:9115-9129, 2007.
 
9) d'Abramo C, et al.:Tau passive immunotherapy in mutant P301L mice:antibody affinity versus specificity. PLoS One. 8(4):e62402, 2013. doi:10.1371/journal.pone.0062402.
 
10) Yanamandra K, et al.:Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 80(2):402-414, 2013.
PubMed
11) Wilkinson D, et al.:Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease(LADDER):a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 13(11):1092-1099, 2014.
PubMed
12) Huang M, et al.:The novel α 7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology(Berl). 231(23):4541-4551, 2014.
 
13) Tsujio I, et al.:Inactivation of glycogen synthase kinase-3 by protein kinase C delta:implications for regulation of tau phosphorylation. FEBS Lett. 469(1):111-117, 2000.
PubMed
14) Kato K, et al.:Protein kinase C stabilizes X-linked inhibitor of apoptosis protein (XIAP) through phosphorylation at Ser(87) to suppress apoptotic cell death. Psychogeriatrics. 11(2):90-97, 2011.
PubMed
P.49 掲載の参考文献
1) Frisoni GB, et al.:The EADC-ADNI harmonized protocol for manual hippocampal segmentation on magnetic resonance:evidence of validity. Alzheimers Dement, 2014 Sep 27. pii:S1552-5260(14)02468-6. doi:10.1016/j.jalz.2014.05.1756. [Epub ahead of print]
 
2) Ashburner J, et al.:Voxel-based morphometry--the methods. Neuroimage, 11:805-821, 2000.
 
3) Ashburner J:A fast diffeomorphic image registration algorithm. Neuroimage, 38:95-113, 2007.
PubMed
4) Hirata Y, et al.:Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett, 382:269-274, 2005.
PubMed
5) Matsuda H, et al.:Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated lie algebra improves the diagnosis of probable Alzheimer Disease. AJNR Am J Neuroradiol, 33:1109-1114, 2012.
PubMed
6) Waragai M, et al.:Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice. J Alzheimers Dis, 41:1207-1222, 2014.
PubMed
7) Tateno A, et al.:Comparison of imaging biomarkers for Alzheimer's disease:amyloid imaging with[18 F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. Int J Geriatr Psychiatry. 2014 Jul 7. doi:10.1002/gps.4173.
 
8) Sperling RA, et al.:Toward defining the preclinical stages of Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement, 7:280-292, 2011.
PubMed
9) Matsuda H:Voxel-based morphometry of brain MRI in normal aging and Alzheimer's disease. Aging Dis, 4:29-37, 2013.
PubMed
10) Whitwell JL, et al.:Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease:a case-control study. Lancet Neurol, 11:868-377, 2012.
PubMed
P.52 掲載の参考文献
1) Hanyu H, et al.:Diagnostic accuracy of single photon emission computed tomography in Alzheimer's disease. Gerontology, 39(5):260-6, 1993.
PubMed
2) Imabayashi E, et al.:Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer's disease from controls using brain perfusion SPECT. J Nucl Med, 45(9):1450-7, 2004.
PubMed
P.58 掲載の参考文献
1) Minoshima S, et al.:A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med, 36(7):1238-1248, 1995.
 
2) Minoshima S, Foster NL, Kuhl DE:Posterior cingulate cortex in Alzheimer's disease. Lancet, 24;344(8926):895, 1994.
 
3) Matsuda H, et al.:Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography. AJNR Am J Neuroradiol, 28(4):731-736, 2007.
PubMed
4) Mizumura S, et al.:Stereotactic statistical imaging analysis of the brain using the easy Z-score imaging system for sharing a normal database. Radiat Med, 24(7):545-552, 2006.
PubMed
5) Sperling RA, et al.:Toward defining the preclinical stages of Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 7:280-292, 2011.
PubMed
P.64 掲載の参考文献
1) Imabayashi E, Matsuda H, Asada T, Ohnishi T, Sakamoto S, Nakano S, Inoue T:Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer's disease from controls using brain perfusion SPECT. J Nucl Med, 45(9):1450-7, 2004.
PubMed
2) Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE:A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med, 36(7):1238-48, 1995.
 
3) Minoshima S, Foster NL, Kuhl DE:Posterior cingulate cortex in Alzheimer's disease. Lancet, 24;344(8926):895, 1994.
 
4) Mizumura S, Kumita S:Stereotactic statistical imaging analysis of the brain using the easy Z-score imaging system for sharing a normal database. Radiat Med, 24(7):545-52, 2006.
PubMed
5) Matsuda H, Mizumura S, Nagao T, Ota T, Iizuka T, Nemoto K, Takemura N, Arai H, Homma A:Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography. AJNR Am J Neuroradiol, 28(4):731-6, 2007.
PubMed
6) McKhann GM et al.:The diagnosis of dementia due to Alzheimer's Disease:recommendation from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 7;263-69, 2011.
PubMed
7) Albert MS et al.:The diagnosis of mild cognitive impairment due to Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers, 7:270-79, 2011
PubMed
8) Sperling RA et al.:Toward defining the preclinical stages of Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 7:280-92, 2011.
PubMed
9) Jack CR Jr et al.:Hypothetical model of dynamic biomarkers of the Alzheimer's pathological of cascade. Lancet Neurol, 9:119-128, 2010.
PubMed
10) Balasa M, Gelpi E, Antonell A, Rey MJ, Sanchez-Valle R, Molinuevo JL, Llado A:Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology, 17;76(20):1720-5, 2011.
 
11) Hof PR, Vogt BA, Bouras C, Morrison JH:Atypical form of Alzheimer's disease with prominent posterior cortical atrophy:a review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Res, 37(24):3609-25, 1997.
PubMed
12) Gorno-Tempini ML, Brambati SM, Ginex V, Ogar J, Dronkers NF, Marcone A, Perani D, Garibotto V, Cappa SF, Miller BL:The logopenic/phonological variant of primary progressive aphasia. Neurology, 14;71(16):1227-34, 2008.
 
13) Marc Teichmann, Aurelie Kas, Claire Boutet, Sophie Ferrieux, Marie Nogues, Dalila Samri, Christina Rogan, Didier Dormont, Bruno Dubois, and Raffaella Migliaccio, Deciphering:Logopenic primary progressive aphasia:a clinical, imaging and biomarker investigation Brain, 136;3474-3488, 2013.
PubMed
P.70 掲載の参考文献
1) Minoshima S, et al.:Metabolic reduction in the posterior cingulate cortex in very early alzheimer's disease. Annals of neurology, 42:85-94, 1997.
PubMed
2) Ishiwata A, et al.:Preclinical evidence of alzheimer changes in progressive mild cognitive impairment:A qualitative and quantitative spect study. Acta neurologica Scandinavica, 114:91-96, 2006.
PubMed
3) Shimizu S, et al.:Spect follow-up study of cerebral blood flow changes during donepezil therapy in patients with alzheimer's disease. Journal of neuroimaging:official journal of the American Society of Neuroimaging, 16:16-23, 2006.
PubMed
4) Nobili F, et al.:Brain perfusion follow-up in alzheimer's patients during treatment with acetylcholinesterase inhibitors. Journal of nuclear medicine:official publication, Society of Nuclear Medicine, 43:983-990, 2002.
PubMed
5) Nakano S, et al.:Donepezil hydrochloride preserves regional cerebral blood flow in patients with alzheimer's disease. Journal of nuclear medicine:official publication, Society of Nuclear Medicine, 42:1441-1445, 2001.
PubMed
6) Bohnen NI, et al.:Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in alzheimer's disease. Journal of neurology, neurosurgery, and psychiatry, 76:315-319, 2005.
PubMed
7) Craig AH, et al.:Cerebral blood flow correlates of apathy in alzheimer disease. Archives of neurology, 53:1116-1120, 1996.
PubMed
8) Mega MS, et al.:Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in alzheimer's disease. J Neuropsychiatry Clin Neurosci, 12:209-218, 2000.
PubMed
9) Hanyu H, et al.:Regional cerebral blood flow patterns and response to donepezil treatment in patients with alzheimer's disease. Dementia and geriatric cognitive disorders, 15:177-182, 2003.
PubMed
10) Okamura N, et al.:In vivo visualization of donepezil binding in the brain of patients with alzheimer's disease. Br J Clin Pharmacol, 65:472-479, 2008.
PubMed
11) Kaasinen V, et al.:Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in alzheimer's disease. Journal of clinical psychopharmacology, 22:615-620, 2002.
PubMed
12) Shinotoh H, et al.:Effect of donepezil on brain acetylcholinesterase activity in patients with ad measured by pet. Neurology, 56:408-410, 2001.
PubMed
13) Keller C, et al.:Long-term effects of galantamine treatment on brain functional activities as measured by pet in alzheimer's disease patients. J Alzheimers Dis, 24:109-123, 2011.
PubMed
14) 松村和浩ほか:アルツハイマー型認知症患者におけるガランタミンおよびメマンチン投与前後のSPECTによる局所脳血流評価. 脳循環代謝, 24:38-44, 2013.
 
15) Cerci SS, et al.:Effect of rivastigmine on regional cerebral blood flow in alzheimer's disease. Adv Ther, 24:611-621, 2007.
PubMed
16) Iida H, et al.:Quantitative mapping of regional cerebral blood flow using iodine-123-imp and spect. Journal of nuclear medicine:official publication, Society of Nuclear Medicine, 35:2019-2030, 1994.
PubMed
17) 水村直:脳動脈閉塞性疾患における最大値参照法を用いた患側大脳半球の経過観察. 核医, 43:253, 2006.
 
18) Sperling RA, et al.:Toward defining the preclinical stages of alzheimer's disease:Recommendations from the national institute on aging-alzheimer's association workgroups on diagnostic guidelines for alzheimer's disease. Alzheimer's & dementia:the journal of the Alzheimer's Association, 7:280-292, 2011.
PubMed
P.76 掲載の参考文献
1) Petersen RC, et al.:Mild cognitive impairment:Clinical characterization and outcome. Arch Neurol, 56:303-308, 1999.
PubMed
2) Peterson RC, et al.:Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol, 62:1160-1163, 2005.
 
3) Albert. MS, et al.:The diagnosis of mild cognitive impairment due to Alzheimer's disease:Recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimer's Dement 7:270-279, 2011.
PubMed
4) Artero S, et al.:Rivised criteria for mild cognitive impairment:validation within a longitudinal population study. Dement Geriatr Cogn Dis, 22:465-470, 2006.
 
5) 橋本道男:生活習慣病と認知症, Dementia Japan:29:9-25, 2015.
 
6) Petersen RC, et al.:Vitamin E and donepezil for the treatment of mild cognitive impairment, N Engl J Med, 352:2379-2388, 2005.
PubMed
P.83 掲載の参考文献
1) Peterson RC:Mild cognitive impairment as a diagnostic entity. J Intern Med. 256:183-194, 2004.
 
2) Jack CR Jr., et al.:Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease;Implications for sequence of pathological events in Alzheimer's disease. Brain 132:1355-1365, 2009.
PubMed
3) 北垣一 著:MRI, CT画像で診るアルツハイマー病. 松田博史, 朝田隆 編, 見て診て学ぶ認知症の画像診断 改訂第2版 II. 各論 1 アルツハイマー病, 137-150, 永井書店, 2010.
 
4) Apostolova LG, et al.:Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps.
 
5) Varon D, et al.;Minimal atrophy of the entorhinal cortex and hippocampus:progression of cognitive impairment. Dementia 31276-283, 2011.
 
6) Schuff N, et al.:MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 1-11, 2009.
PubMed
7) Duara R, et al.:The utility of age-specific cut-offs for visual rating of medial temporal atrophy in classifying Alzheimer's disease, MCI and cognitively normal elderly subjects. Frontiers in Aging Neuroscience 5:47:1-8, 2013.
 
8) Minoshima S, et al.:Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Nurol 42:85-94, 1997.
 
9) Kogure D, et al.:Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med 41:1155-1162, 2000.
PubMed
10) Matsuda H, et al.:Brain SPET abnormalities in Alzheimer's disease before and after atrophy correction. Eur J Nucl Med Mol Imaging 29:1502-1505, 2002.
PubMed
11) Imabayashi E, et al.:Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer's disease from controls using brain perfusion SPECT. J Nucl Med 45:1450-1457, 2004.
PubMed
12) Herholz K, et al.:Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med 43:21-26, 2002.
PubMed
13) Ito K, et al.:Prediction of outcomes in MCI with 123I-IMP-CBF SPECT:a multicenter prospective cohort study. Ann Nucl Med 27:898-906, 2013.
 
14) Hirano K, et al.:The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional blood flow SPECT. Neuroimage 28:1014-1021, 2005.
 
15) Li X, et al.:Correlations between Z-scores of VSRAD and regional cerebral blood flow of SPECT in patients with Alzheimer's disease and mild cognitive impairment. Psychiatry and Clinical neurosciences 64:284-292, 2010.
PubMed

II 認知症の画像診断 - 鑑別診断 -

P.92 掲載の参考文献
1) Glenner GG et al.:Alzheimer's disease:initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun, 120:885-890, 1984.
PubMed
2) Masters CL et al.:Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA, 82:4245-4249, 1985.
PubMed
3) Kang J et al.:The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature, 325:733-736, 1987.
PubMed
4) Hutton M et al.:Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature, 393:702-705, 1998.
 
5) Frost B et al.:Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem, 284:12845-12852, 2009.
 
6) Cruts M et al.:Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature, 442:920-924, 2006.
PubMed
7) Barker M et al.:Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 442:916-919, 2006.
 
8) Neumann M et al.:Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314:130-133, 2006.
 
9) Arai T et al.:TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun, 351:602-611, 2006.
PubMed
10) Yamashita T et al.:A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nature communications, 3:1307, 2012.
PubMed
11) Polymeropoulos MH et al.:Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276:2045-2047, 1997.
PubMed
12) Spillantini MG et al.:Alpha-synuclein in Lewy bodies. Nature, 388:839-840, 1997.
PubMed
13) Luk KC, et al.:Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science, 338:949-953, 2012.
PubMed
14) The Huntington's Disease Collaborative Research Group:Cell 72:971-983, 1993.
 
P.98 掲載の参考文献
1) McKeith IG, et al.:Diagnosis and management of dementia with Lewy bodies:third report of the DLB Consortium. Neurology, 65:1863-1872, 2005.
PubMed
2) Rascovsky K, et al.:Sensitivity of revised diagnostic criteria for the behavioral variant of frontotemporal dementia. Brain, 134:2456-2477.
PubMed
3) Neary D, et al.:Frontotemporal lobar degeneration:a consensus on clinical diagnostic criteria. Neurology, 51:1546-1554, 1998.
 
P.106 掲載の参考文献
1) McKeith IG, et al.:Diagnosis and management of dementia with Lewy bodies:third report of the DLB Consortium. Neurology, 65:1863-18672, 2005.
PubMed
2) Takahashi R, et al.:Measurement of gray and white matter atrophy in dementia with lewy bodies using diffeomorphic anatomic registration through exponentiated lie algebra:A comparison with conventional voxel-based morphometry. AJNR Am J Neuroradiol, 31:1873-1878, 2010.
PubMed
3) Ishii K, et al.:Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology, 53:413-416, 1999.
 
4) Ishii K, et al.:Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Ann Nucl Med, 18:447-451, 2004.
PubMed
5) Varrone A, et al.:Voxel-based comparison of rCBF SPET images in frontotemporal dementia and Alzheimer's disease highlights the involvement of different cortical networks. Eur J Nucl Med Mol Imaging, 29:1447-1454, 2002.
PubMed
6) Takahashi R, et al.:Brain alterations and mini-mental state examination in patients with progressive supranuclear palsy:voxel-based investigations using 18F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging. Dement Geriatr Cogn Disord Extra, 1:381-392, 2011.
 
7) 篠遠仁 ほか:CBSにおける画像診断. Brain and Nerve, 65:41-53, 2013.
 
P.118 掲載の参考文献
1) 日本正常圧水頭症学会特発性正常圧水頭症診療ガイドライン作成委員会:特発性正常圧水頭症診療ガイドライン第2版. メディカルレビュー社, 大阪, 2011.
 
2) Mori E, et al.:Guidelines for management of idiopathic normal pressure hydrocephalus:second edition. Neurologia medico-chirurgica 52(11):775-809, 2012.
PubMed
3) Jaraj D, et al.:Prevalence of idiopathic normal-pressure hydrocephalus. Neurology 82(16):1449-54, 2014.
PubMed
4) Bech-Azeddine R, et al.:Idiopathic normal-pressure hydrocephalus;Evaluation and findings in a multidisciplinary memory clinic. Eur J Neurol 8:601-11, 2001.
 
5) Nakajima M, et al.:Use of External Lumbar Cerebrospinal Fluid Drainage and Lumboperitoneal Shunts with Strata NSC Valves in Idiopathic Normal Pressure Hydrocephalus:A Single-Center Experience. World Neurosurg 2014. http://dx.doi.org/10.1016/j.wneu.2014.08.004
 
6) Kazui H, et al.:Lumboperitoneal shunt surgery for idiopathic normal pressure hydrocephalus(SINPHONI-2):an open-label randomised trial. Lancet Neurol 14(6):585-594, 2015.
PubMed
7) Hashimoto M, et al.:Diagnosis of idiopathic normal pressure hydrocephalus is supported by MRI-based scheme:a prospective cohort study. Cerebrospinal Fluid Res;7:18, 2010.
PubMed
8) Adachi M, et al.:Upper midbrain profile sign and cingulate sulcus sign:MRI findings on sagittal images in idiopathic normal-pressure hydrocephalus, Alzheimer's disease, and progressive supranuclear palsy. Radiat Med 24:568-572, 2006.
PubMed
9) Kitagaki H, et al.:CSF spaces in idiopathic normal pressure hydrocephalus:morphology and volumetry. AJNR Am J Neuroradiol. 19(7):1277-84, 1998.
 
10) Yamashita F, et al.:Detection of changes in cerebrospinal fluid space in idiopathic normal pressure hydrocephalus using voxel-based morphometry. Neuroradiology 52:381-386, 2010.
PubMed
11) Ishii K, et al.:Clinical impact of the callosal angle in the diagnosis of idiopathic normal pressure hydrocephalus. Eur Radiol 18(11):2678-83, 2008.
PubMed
12) Oi S, et al.:Pathophysiology of long-standing overt ventriculomegaly in adults. J Neurosurg. 92(6):933-40, 2000.
PubMed
13) Iseki C, et al.:Asymptomatic ventriculomegaly with features of idiopathic normal pressure hydrocephalus on MRI(AVIM)in the elderly:A prospective study in a Japanese population. J Neurol Sci 277(1-2):54-57, 2009.
 
14) Ishii K, et al.:A multicenter brain perfusion SPECT study evaluating idiopathic normal-pressure hydrocephalus on neurological improvement. Dement Geriatr Cogn Disord 32:1-10, 2011.
 
15) Takaya M, et al.:Global cerebral hypoperfusion in preclinical stage of idiopathic normal pressure hydrocephalus. J Neurol Sci 298(1-2):35-41, 2010.
 
16) 徳田隆彦:髄液の産生・吸収障害と特発性正常圧水頭症の新しい画像診断. 臨床神経学 54(12):1193-1196, 2014.
 
17) 吉山顕次ほか:認知症疾患医療センターにおける特発性正常圧水頭症診療の現状 BRAIN and NERVE(印刷中)
 
P.128 掲載の参考文献
1) Philip B Gorelick, et al.:Vascular contributions to cognitiveimpairment and dementia:a statement for healthcare professionals from the american heart association/american stroke association. Stroke:42(9);2672-713, 2011.
 
2) 朝田隆:有病率どこまで増える認知症. 臨床神経, 52:962-964, 2012.
 
3) Hachinski VC, et al.:Cerebral blood flow in dementia. Arch Neurol 32:632-637, 1975.
PubMed
4) Pohjasvaara T, et al.:Comparison of different clinical criteria(DSM-IV, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the dignosis of vascular dementia. Stroke, 31:2952-2957, 2000.
 
5) 大野裕, 高橋三郎 監訳:DSM-5 精神疾患の診断・統計マニュアル, 用語監修日本精神神経学会, 612-615, 医学書院, 2014.
 
6) Roman GC, et al.:Vascular dementia:Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250-260, 1993.
 
7) Chui HC, et al.:Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 42:473-480, 1992.
PubMed
8) 北村伸 ほか:痴呆性疾患の画像診断シリーズ2 脳血管性痴呆, 1-31, ワールドプランニング, 1997.
 
P.134 掲載の参考文献
1) Biessels GJ, et al.:Risk of dementia in diabetes mellitus:a systemic review. Lancet Neurol 5:64-74, 2006.
 
2) Fukazawa R, et al.:Subgroups of Alzheimer's disease associated with diabetes mellitus based on brain imaging. Dement Geriatr Cogn Disord 35:280-290, 2013.
PubMed
3) Fukasawa R, et al.:Identification of diabetes-related dementia:longitudinal perfusion SPECT and PiB PET studies. J Neurol Sci 349:45-51, 2015
PubMed
4) Hanyu H, et al.:Guidelines for the clinical diagnosis of diabetes-related dementia. J Am Geriatr Soc(in press).
 
5) 村山繁雄 ほか:糖代謝異常からみた認知症の脳病理. 月刊糖尿病, 4(9):48-56, 2012.
 
6) Kalaria RN:Diabetes, microvascular pathology and Alzheimer disease. Nat Rev Neurol 5:305-306, 2009.
PubMed
7) 羽生春夫:糖尿病と認知症. Brain and Nerve, 66:129-134, 2014.
 
8) 羽生春夫, 深澤雷太:糖尿病を合併した認知症患者の脳画像. 医学のあゆみ 249:517-521, 2014.
 
9) Brundel M, et al.:Cerebral microvascular lesions on high-resolution 7-tesla MRI in patients with type 2 diabetes. Diabetes, 63:3523-3529, 2014.
PubMed
10) Hirao K, et al.:A longitudinal SPECT study of different patterns of regional cerebral blood flow in Alzheimer's disease with or without diabetes. Dement Geriatr Cogn Dis Extra, 1:62-74, 2011.
PubMed

III 認知症の画像診断 - 将来展望 -

P.143 掲載の参考文献
1) Cummings JL, et al.:The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain, 134:3146-3166, 2011.
PubMed
2) Papathanasiou ND, et al.:Diagnostic accuracy of 123I-FP-CIT(DaTSCAN)in DLB:a meta-analysis of published studies. Parkinsonism Relat Disord, 18:225-229, 2012.
PubMed
3) 日本核医学会, 日本脳神経核医学研究会 編.:イオフルパン診療ガイドライン. 2014年.
 
4) Booij, et al.:effects of paroxetine on FP-CIT binding. J Nucl Med, 48:359-366, 2007.
 
5) Tossici-Bolt, et al.:Quantification of [123I] FP-CIT SPECT brain images:an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging, 33:1491-1499, 2006.
PubMed
6) Ferman TJ, et al.:Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology, 81:2032-2038, 2013.
PubMed
7) Tolosa E, et al.:Accuracy of DaTSCAN(123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism:2-year follow-up of an open-label study. Mov Disord, 22:2346-2351, 2007.
PubMed
8) Siepel FJ, et al.:(123I) FP-CIT SPECT in suspected dementia with Lewy bodies:a longitudinal case study. BMJ Open, doi:10.1136/bmjopen-2013-002642.
 
9) Booij J, et al.:[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol, Neurosurg Psych, 62:133-140, 1997.
 
10) Del Sole A, et al.:Correlation between 123I-FP-CIT brain SPECT and parkinsonism in dementia with Lewy bodies:caveat for clinical use. Clin Nucl Med, 40:32-35, 2015.
PubMed
11) Walker Z, et al.:Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease:a comparison. Neurology, 62:1568-1572, 2004.
PubMed
12) Ziebell M, et al.:Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies. J Nucl Med, 54:1072-1076, 2013.
 
13) Roselli F, et al.:Severity of neuropsychiatric symp- toms and dopamine transporter levels in dementia with Lewy bodies:A 123I-FP-CIT SPECT study. Mov Disord, 24:2097-2103, 2009.
 
14) Braak H, et al.:Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24:197-211, 2003.
PubMed
P.152 掲載の参考文献
1) Magistretti PJ:Role of glutamate in neuron-glia metabolic coupling. Am J Clin Nutr 90(3):875S-880S, 2009.
PubMed
2) Weiner MW, et al.:The Alzheimer's Disease Neuroimaging Initiative:a review of papers published since its inception. Alzheimers Dement 9(5):111-194, 2013.
 
3) McKhann GM, et al.:The diagnosis of dementia due to Alzheimer's disease:Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3):263-269, 2011.
PubMed
4) Albert MS, et al.:The diagnosis of mild cognitive impairment due to Alzheimer's disease:Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3):270-279, 2011.
PubMed
5) Sperling RA, et al.:Toward defining th preclinical stages of Alzheimer's disease:Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3):280-292, 2011.
 
6) Minoshima S, et al.:Posterior cingulate cortex in Alzheimer's disease. Lancet 344(8926):895, 1994.
PubMed
7) Mielke R, et al.:Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol 91(2):174-179, 1996.
PubMed
8) Herholz K, et al.:Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med 43(1):21-26, 2002.
PubMed
9) Silverman DH:Brain 18F-FDG PET in the Diagnosis of Neurodegenerative Dementias:Comparison with Perfusion SPECT and with Clinical Evaluations Lacking Nuclear Imaging*. J Nucl Med 45(4):594-607, 2004.
PubMed
10) Ishii K, et al.:Relatively preserved hippocampal glucose metabolism in mild Alzheimer's disease. Dement Geriatr Cogn Disord 9(6):317-322, 1998.
PubMed
11) Mielke R, et al.:Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol Aging 13(1):93-98, 1992.
PubMed
12) Sakamoto S, et al.:Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J Neurol Sci 200(1-2):27-32, 2002.
 
13) Whitwell JL, et al.:Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease:a case-control study. Lancet Neurol 11;868-877, 2012.
PubMed
14) Minoshima S, et al.:Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 42(1):85-94, 1997.
PubMed
15) Raichle ME, et al.:A default mode of brain function. Proc Natl Acad Sci USA, 98:676-682, 2001.
PubMed
16) Minoshima S, et al.:A diagnostic approach in Alzheimer's disease using three-dimensional stereotractic surface projections of fluorine-18-FDG PET. J Nucl Med 36(7):1238-1248, 1995.
 
17) Duara R, et al.:Sensitivity and specificity of positron emission tomography and magnetic resonance imaging studies in Alzheimer's disease and multi-infarct dementia. Eur Neurol 29(3):9-15, 1989.
 
18) Herholz K, et al.:Criteria for the diagnosis of Alzheimer's disease with positron emission tomography. Dementia 1:156-164, 1990.
 
19) Szelies B, et al.:Quantitative topographical EEG compared to FDG PET for classification of vascular and degenerative dementia. Electroencephalogr Clin Neurophysiol 91(2):131-139, 1994.
PubMed
20) von Borczyskowski D, et al.:Evaluation of a new expert system for fully automated detection of the Alzheimer's dementia pattern in FDG PET. Nucl Med Commun 27(9):739-743, 2006.
PubMed
21) Ishii K, et al.:Fully automatic diagnostic system for early-and late-onset mild Alzheimer's disease using FDG PET and 3D-SSP. Eur J Nucl Med Mol Imaging 33(5):575-583, 2006.
PubMed
22) Matsunari I, et al.:Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer's disease:aging effect on diagnostic performance. J Nucl Med 48(12):1961-1970, 2007.
PubMed
23) Mosconi L, et al.:Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 49(3):390-398, 2008.
PubMed
24) Haense C, et al.:Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples(NEST-DD and ADNI). Dement Geriatr Cogn Disord 28(3):259-266, 2009.
PubMed
25) McMurtray AM, et al.:Positron emission tomography facilitates diagnosis of early-onset Alzheimer's disease. Eur Neurol 59(1-2):31-37, 2008.
 
26) Chen K, et al.:Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 56(1):52-60, 2011.
PubMed
27) Bloudek LM, et al.:Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J Alzheimers Dis. 26(4):627-645, 2011.
PubMed
28) Bohnen NI, et al.:Effectiveness and safety of 18F-FDG PET in the evaluation of dementia:a review of the recent literature. J Nucl Med 53(1):59-71, 2012.
PubMed
29) Ishii K, et al.:Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 51(1):125-130, 1998.
PubMed
30) Higuchi M, et al.:Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 62(2):247-256, 2000.
 
31) Kono AK, et al.:Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP. Eur J Nucl Med Mol Imaging 34(9):1490-1497, 2007.
PubMed
32) Foster NL, et al.:FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 130(Pt 10):2616-2635, 2007.
 
33) Salmon E, et al.:differential diagnosis of Alzheimer's disease with PET. J Nucl Med 35(3):391-398, 1994.
 
34) Hoffman JM, et al.:FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 41(11):1920-1928, 2000.
PubMed
35) Silverman DH, et al.:Positron emission tomography in evaluation of dementia:Regional brain metabolism and long-term outcome. JAMA 7;286(17):2120-2127, 2001.
 
36) Jagust W, et al.:What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 28;69(9):871-877, 2007.
 
37) McKeith IG, et al.:Consortium on DLB. Diagnosis and management of dementia with Lewy bodies. Neurology 65:1-10, 2005.
 
38) Petersen RC:Mild cognitive impairment as a diagnostic entity. J Intern Med 256(3):183-94, 2004.
PubMed
39) Petersen RC, et al.:Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 62(7):1160-1163, 2005.
PubMed
40) Mosconi L, et al.:MCI conversion to dementia and the APOE genotype:a prediction study with FDG-PET. Neurology 28;63(12):2332-2340, 2004.
 
41) Drzezga A, et al.:Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 46(10):1625-1632, 2005.
 
42) Anchisi D, et al.:Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 62(11):1728-1733, 2005.
PubMed
43) Yuan Y, et al.:Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment:a meta-analysis. Am J Neuroradiol 30:404-410, 2009.
PubMed
44) Herholz K, et al.:Evaluation of a calibrated(18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med 52(8):1218-26, 2011.
PubMed
45) Ito K, et al.:Prediction of outcomes in MCI by using 18F-FDG-PET:A multicenter study. J Alzheimers Dis 45:543-552, 2015.
PubMed
46) Ito K, et al.:Prediction of outcomes in MCI with(123)I-IMP-CBF SPECT:a multicenter prospective cohort study. Ann Nucl Med 27(10):898-906, 2013.
PubMed
47) Small GW, et al.:Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273(12):942-947, 1995.
PubMed
48) Reiman EM, et al.:Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for apolipoprotein E. N Engl J Med 334(12):752-758, 1996.
 
49) Reiman EM, et al.:Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 101(1):284-289, 2004.
PubMed
50) Small GW, et al.:Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 97(11):6037-6042, 2000.
PubMed
51) de Leon MJ, et al.:Prediction of cognitive decline in normal elderly subjects with 2-F-18-fluoro-2-deoxy-d-glucose positron-emission tomography(FDG-PET). Proc Natl Acad Sci USA 98(19):10966-10971, 2001.
 
52) Jack CR Jr, et al.:An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71(6):765-775, 2012.
PubMed
53) Knopman DS, et al.:Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol 73(4):472-480, 2013.
 
54) Wirth M, et al.:Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 70(12):1512-1519, 2013.
PubMed
P.161 掲載の参考文献
1) Hardy J:Alzheimer's disease. the amyloid cascade hypothesis, an update and reappraisal. J Alzheimers Dis, 9:151-153, 2006.
PubMed
2) McKhann GM, et al.:The diagnosis of dementia due to Alzheimer's disease. Alzheimers Dement, 7:263-269, 2011.
PubMed
3) Albert MS, et al.:The diagnosis of mild cognitive impairment due to Alzheimer's disease. Alzheimers Dement, 7:270-279, 2011.
PubMed
4) Sperling RA, et al.;Toward defining the preclinical stages of Alzheimer's disease. Alzheimers Dement, 7:280-292, 2011.
PubMed
5) Klunk WE, et al.:Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol, 55:306-319, 2004.
PubMed
6) Klunk WE, et al.:The Centiloid Project:Standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement, 11:1-15, 2015.
PubMed
7) 日本核医学会, 日本認知症学会, 日本神経学会編:厚生労働省研究班「アミロイドイメージングを用いたアルツハイマー病発症リスク予測法の実用化に関する多施設臨床研究」. アミロイドPET イメージング剤合成装置の適正使用ガイドライン 第1版, 2015. 日本核医学会ホームページ掲載 http://www.jsnm.org/japanese/15-06-09
 
P.167 掲載の参考文献
1) Dickson DW:Neuropathological diagnosis of Alzheimer's disease:a perspective from longitudinal clinicopathological studies. Neurobiology of aging 18, S21-26, 1997.
PubMed
2) Klunk WE, et al.:Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of neurology 55, 306-319, 2004.
PubMed
3) Lee VM, et al.:Neurodegenerative tauopathies. Annu Rev Neurosci 24, 1121-1159, 2001.
PubMed
4) Hutton M, et al.:Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705, 1998.
 
5) Poorkaj P, et al.:Tau is a candidate gene for chromosome 17 frontotemporal dementia. Annals of neurology 43, 815-825, 1998.
PubMed
6) Ebneth A, et al.:Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum:implications for Alzheimer's disease. The Journal of cell biology 143, 777-794, 1998.
PubMed
7) Shoghi-Jadid K, et al.:Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. The American journal of geriatric psychiatry:official journal of the American Association for Geriatric Psychiatry 10, 24-35, 2002.
PubMed
8) Chien DT, et al.:Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. Journal of Alzheimer's disease:JAD 34, 457-468, 2013.
PubMed
9) Chien DT, et al.:Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808. Journal of Alzheimer's disease:JAD 38, 171-184, 2014.
PubMed
10) Harada R, et al.:Use of a Benzimidazole Derivative BF-188 in Fluorescence Multispectral Imaging for Selective Visualization of Tau Protein Fibrils in the Alzheimer's Disease Brain. Molecular imaging and biology:MIB:the official publication of the Academy of Molecular Imaging, 2013.
 
11) Okamura N, et al.:Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. Journal of nuclear medicine:official publication, Society of Nuclear Medicine 54, 1420-1427, 2013.
PubMed
12) Harada R, et al.:[F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. European journal of nuclear medicine and molecular imaging, 2015.
PubMed
13) Maruyama M, et al.:Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094-1108, 2013.
 
14) Villemagne VL, Fodero-Tavoletti MT, Masters CL & Rowe CC:Tau imaging:early progress and future directions. Lancet neurology 14, 114-124, 2015.
PubMed
15) Braak H & Braak E:Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica 82, 239-259, 1991.
PubMed

書評

最近チェックした商品履歴

Loading...